$2.34
0.052.18%
At Close: -
$2.26
-0.08-3.42%
After Hours: 8:59 AM EDT
15 minutes delayed
Ventyx Biosciences
VTYXNASDAQ
want to know what
the Bulls & Bears Say?
Ventyx Biosciences (NASDAQ:VTYX) Stock, Analyst Ratings, Price Targets, Forecasts
Ventyx Biosciences Inc has a consensus price target of $24.83 based on the ratings of 45 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co. on June 13, 2024, June 6, 2024, and June 6, 2024, respectively. With an average price target of $7.33 between HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co., there's an implied 224.48% upside for Ventyx Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
Canaccord Genuity
Wells Fargo
Stifel
1calculated from analyst ratings
Analyst Ratings for Ventyx Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/13/2024 | Buy Now | 165.49% | HC Wainwright & Co. | Emily Bodnar | $6 → $6 | Reiterates | Neutral → Neutral | Get Alert |
| 06/06/2024 | Buy Now | 342.48% | Oppenheimer | Jeff Jones | $12 → $10 | Maintains | Outperform | Get Alert |
| 06/06/2024 | Buy Now | 165.49% | HC Wainwright & Co. | Emily Bodnar | $6 → $6 | Reiterates | Neutral → Neutral | Get Alert |
| 03/13/2024 | Buy Now | 563.72% | Canaccord Genuity | Edward Nash | $16 → $15 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 430.97% | Oppenheimer | Jeff Jones | → $12 | Upgrade | Perform → Outperform | Get Alert |
| 03/12/2024 | Buy Now | 607.96% | Wells Fargo | Derek Archila | $7 → $16 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/11/2024 | Buy Now | 607.96% | Canaccord Genuity | Edward Nash | $20 → $16 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | — | Oppenheimer | Jeff Jones | — | Reiterates | → Perform | Get Alert |
| 12/19/2023 | Buy Now | 32.74% | Wells Fargo | Derek Archila | $8 → $3 | Maintains | Equal-Weight | Get Alert |
| 12/18/2023 | Buy Now | -11.5% | Stifel | Alex Thompson | $6 → $2 | Maintains | Hold | Get Alert |
| 11/10/2023 | Buy Now | 121.24% | Evercore ISI Group | Josh Schimmer | $43 → $5 | Downgrade | Outperform → In-Line | Get Alert |
| 11/07/2023 | Buy Now | 165.49% | Morgan Stanley | Vikram Purohit | $46 → $6 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/07/2023 | Buy Now | 165.49% | Stifel | Alex Thompson | → $6 | Downgrade | Buy → Hold | Get Alert |
| 11/07/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar | — | Downgrade | Buy → Neutral | Get Alert |
| 10/10/2023 | Buy Now | 2377.88% | Stifel | Alex Thompson | → $56 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2023 | Buy Now | 2200.88% | HC Wainwright & Co. | Emily Bodnar | → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/29/2023 | Buy Now | 1935.4% | Morgan Stanley | Simon Flannery | $45 → $46 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 2643.36% | Credit Suisse | Tiago Fauth | $63 → $62 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 2200.88% | HC Wainwright & Co. | Emily Bodnar | $54 → $52 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | 2643.36% | Oppenheimer | Jeff Jones | → $62 | Reiterates | Outperform → Outperform | Get Alert |
| 07/05/2023 | Buy Now | 2289.38% | HC Wainwright & Co. | Emily Bodnar | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 2687.61% | Credit Suisse | Tiago Fauth | → $63 | Assumes | → Outperform | Get Alert |
| 05/12/2023 | Buy Now | 2289.38% | HC Wainwright & Co. | Emily Bodnar | → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/24/2023 | Buy Now | 2687.61% | Credit Suisse | Tiago Fauth | → $63 | Reiterates | → Outperform | Get Alert |
| 03/24/2023 | Buy Now | 2643.36% | Oppenheimer | Jeff Jones | $65 → $62 | Maintains | Outperform | Get Alert |
| 03/21/2023 | Buy Now | 3307.08% | Wells Fargo | Derek Archila | → $77 | Initiates | → Overweight | Get Alert |
| 03/20/2023 | Buy Now | 2112.39% | HC Wainwright & Co. | Emily Bodnar | → $50 | Reiterates | → Buy | Get Alert |
| 01/31/2023 | Buy Now | 2289.38% | Canaccord Genuity | Edward Nash | $35 → $54 | Maintains | Buy | Get Alert |
| 01/27/2023 | Buy Now | 2554.87% | Oppenheimer | Jeff Jones | $55 → $60 | Maintains | Outperform | Get Alert |
| 12/19/2022 | Buy Now | 2112.39% | Goldman Sachs | Chris Shibutani | → $50 | Initiates | → Buy | Get Alert |
| 11/17/2022 | Buy Now | 1891.15% | Morgan Stanley | Simon Flannery | → $45 | Initiates | → Overweight | Get Alert |
| 09/16/2022 | Buy Now | 2245.13% | Stifel | Alex Thompson | $45 → $53 | Maintains | Buy | Get Alert |
| 09/13/2022 | Buy Now | 2112.39% | HC Wainwright & Co. | Emily Bodnar | $36 → $50 | Maintains | Buy | Get Alert |
| 09/12/2022 | Buy Now | 2776.11% | Oppenheimer | Jeff Jones | $40 → $65 | Maintains | Outperform | Get Alert |
| 09/07/2022 | Buy Now | 1891.15% | Stifel | Alex Thompson | → $45 | Initiates | → Buy | Get Alert |
| 09/01/2022 | Buy Now | 1492.92% | HC Wainwright & Co. | Emily Bodnar | → $36 | Initiates | → Buy | Get Alert |
| 08/17/2022 | Buy Now | 1448.67% | Canaccord Genuity | Edward Nash | $30 → $35 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | 2687.61% | Credit Suisse | Tiago Fauth | $53 → $63 | Maintains | Outperform | Get Alert |
| 08/16/2022 | Buy Now | 1669.91% | Oppenheimer | Jeff Jones | $30 → $40 | Maintains | Outperform | Get Alert |
| 05/09/2022 | Buy Now | 2245.13% | Credit Suisse | Tiago Fauth | → $53 | Initiates | → Outperform | Get Alert |
| 03/31/2022 | Buy Now | 1227.43% | Canaccord Genuity | Edward Nash | → $30 | Initiates | → Buy | Get Alert |
| 02/01/2022 | Buy Now | 1227.43% | Oppenheimer | Jeff Jones | → $30 | Initiates | → Outperform | Get Alert |
| 11/15/2021 | Buy Now | 2112.39% | Evercore ISI Group | Josh Schimmer | — | Initiates | → Outperform | Get Alert |
| 11/15/2021 | Buy Now | 1227.43% | Jefferies | Michael Yee | — | Initiates | → Buy | Get Alert |
| 11/15/2021 | Buy Now | 2112.39% | Piper Sandler | Yasmeen Rahimi | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Ventyx Biosciences (VTYX) stock?
The latest price target for Ventyx Biosciences (NASDAQ:VTYX) was reported by HC Wainwright & Co. on June 13, 2024. The analyst firm set a price target for $6.00 expecting VTYX to rise to within 12 months (a possible 165.49% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ventyx Biosciences (VTYX)?
The latest analyst rating for Ventyx Biosciences (NASDAQ:VTYX) was provided by HC Wainwright & Co., and Ventyx Biosciences reiterated their neutral rating.
When was the last upgrade for Ventyx Biosciences (VTYX)?
The last upgrade for Ventyx Biosciences Inc happened on March 12, 2024 when Oppenheimer raised their price target to $12. Oppenheimer previously had a perform for Ventyx Biosciences Inc.
When was the last downgrade for Ventyx Biosciences (VTYX)?
The last downgrade for Ventyx Biosciences Inc happened on November 10, 2023 when Evercore ISI Group changed their price target from $43 to $5 for Ventyx Biosciences Inc.
When is the next analyst rating going to be posted or updated for Ventyx Biosciences (VTYX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ventyx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ventyx Biosciences was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.
Is the Analyst Rating Ventyx Biosciences (VTYX) correct?
While ratings are subjective and will change, the latest Ventyx Biosciences (VTYX) rating was a reiterated with a price target of $6.00 to $6.00. The current price Ventyx Biosciences (VTYX) is trading at is $2.26, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.